The Penn spinout launched a year ago with CAR-T pioneer Carl June as a scientific co-founder and $216 million in funding from private investors. It dosed its first patient in a clinical trial.
Dispatch Bio launches its first clinical trial to develop a universal treatment for solid cancers
